SCHEMBL10104547

SCHEMBL10104547

Cc1cc(OC(F)(F)F)cc(N(C)C2CCN(C)C2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.44
MCHR1 Q99705 3/20 0.39
FFAR4 Q5NUL3 1/20 0.38
HTR6 P50406 1/20 0.35
KCNH2 Q12809 3/20 0.33
PIM2 Q9P1W9 2/20 0.33
CCR6 P51684 1/20 0.33
OPRM1 P35372 1/20 0.33
CACNA2D1 P54289 1/20 0.33
CCR5 P51681 1/20 0.33
IL1B P01584 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
HTR2C P28335 3/20 0.32
PIM1 P11309 1/20 0.32
PIM3 Q86V86 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PGR P06401 2/20 0.31
AR P10275 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104344 0.92 HTR2A (0.48) HTR2AMCHR1FFAR4HTR6PIM2
SCHEMBL10104292 0.82 HTR2A (0.39) HTR2AMCHR1FFAR4KCNH2IL1B
SCHEMBL2056172 0.73 HTR2A (0.62) HTR2AMCHR1HTR6KCNH2CCR6
SCHEMBL10104327 0.73 HTR2A (0.44) HTR2AMCHR1FFAR4IL1BNOS3
SCHEMBL15829964 0.72 HTR2A (0.50) HTR2AHTR2CPGR
SCHEMBL10104544 0.71 FFAR4 (0.47) HTR2AMCHR1FFAR4PIM2PIM1
SCHEMBL10104398 0.69 NOS3 (0.38) HTR2AMCHR1KCNH2NOS3NOS1
SCHEMBL10104348 0.68 SLC6A3 (0.51) PIM2PIM3ALDH1A1
SCHEMBL26251715 0.66 HTR2A (0.47) HTR2AMCHR1HTR6KCNH2CCR6
SCHEMBL26251719 0.66 HTR2A (0.47) HTR2AMCHR1HTR6KCNH2CCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 HTR2A 4089/4885MCHR1 1015/4885FFAR4 4204/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 HTR2A 2935/4885MCHR1 3560/4885FFAR4 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.